Locost Opposition, Lenacapavir, (In201917006277)
No Annotations
Alert me when there are new annotations for this document
10 similar patent oppositions
-
AIDS HEALTHCARE FOUNDATION [AHF] opposition, Lenacapavir, (202017010006)
Countries: India Date: 2025
-
AIDS HEALTHCARE FOUNDATION [AHF] opposition, Lenacapavir, (202017007904)
Countries: India Date: 2025
-
Vietnam Network of People Living with HIV (VNP+) opposition, Rilpivirine, (PCT/US2021/072453)
Countries: Viet Nam Date: 2025
-
Thai Network of People Living with HIV/AIDS (TNP+) opposition, Rilpivirine, (WO/2012/068535)
Countries: Thailand Date: 2025
-
People PLUS opposition, Rilpivirine, (EA202391454)
Countries: Europe (EPO) Date: 2025
-
Fundación Grupo Efecto Positivo (FGEP) opposition, Dolutegravir pediatric dispersible tablet, (P20210101730 (AR122718A1) )
Countries: Argentina Date: 2025
-
Fundación Grupo Efecto Positivo opposition, Dolutegravir pediatric combination, (P20210101732 (AR122720A1))
Countries: Argentina Date: 2025
-
ABIA (Associação Brasileira Interdisciplinar de AIDS) opposition, Lenacapavir prodrug (GS-4182), (BR112024010162)
Countries: Brazil Date: 2025
-
MSN Laboratories Pvt. Ltd. opposition, Upadacitinib [RINVOQ], (4759/DELNP/2012)
Countries: India Date: 2025
-
Mylan Laboratories India opposition, Raltegravir, (4187/DELNP/2007)
Countries: India Date: 2018